pharma is the sole category represented across all 1 tracked stories. Biden Administration is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 5 original sources on average. We currently track 1 Biotech story that mention Inflation Reduction Act, all published on July 30, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Inflation Reduction Act
pharma is the sole category represented across all 1 tracked stories. Biden Administration is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 5 original sources on average. We currently track 1 Biotech story that mention Inflation Reduction Act, all published on July 30, 2026.
Stories tracked
1
Sources per story
5
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Inflation Reduction Act. Shared-story counts are live from our verified record — not editorial picks.
Termination of the temporary Medicare Part D subsidy by the Trump administration could shift $3.6 billion in costs, affecting drug pricing dynamics and patient adherence, with implications for pharma and biotech companies reliant on senior populations.